[225Ac]Ac-DOTA-Trastuzumab F(ab’)2

N/A

Report date: 2025/10/28 16:07:02

Base Information

Drug Name[225Ac]Ac-DOTA-Trastuzumab F(ab’)2

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity of Toronto

China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Toronto

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A